Welcome to our dedicated page for Invitro Internat news (Ticker: IVRO), a resource for investors and traders seeking the latest updates and insights on Invitro Internat stock.
The IVRO news page on Stock Titan compiles press releases and updates from InVitro International, a company that describes itself as a pioneer developer and marketer of globally approved NON-Animal test technologies. These news items provide context on how the business connects its in vitro safety testing methods with regulatory, financial, and strategic developments.
Readers can find detailed announcements about quarterly and annual financial results, where InVitro International reports sales, net income, and commentary on profitability. Management statements in these releases often discuss how economic conditions, such as Covid-related and inflationary challenges, intersect with the company’s long-term focus on non-animal testing and its plans for growth.
News coverage also highlights regulatory and legislative changes that affect the adoption of non-animal testing. InVitro International’s releases reference actions by regulatory agencies and governments, including decisions to stop funding animal testing, accept OECD-validated non-animal test results, and restrict cosmetics that rely on animal testing. The company frames these developments as supportive of its NON-Animal test technologies.
Another recurring theme in IVRO news is corporate strategy and M&A activity. The company reports on its intent to grow both organically and through mergers and acquisitions, including a Memorandum of Understanding to merge with a European-based non-animal testing focused organization and efforts to qualify privately owned candidate laboratories. It also announces engagements with advisory firms and plans to apply for an uplisting to OTCQB.
For investors and observers interested in non-animal safety testing, animal welfare trends, and IVRO’s financial and strategic progress, this news page offers an organized view of the company’s public communications over time.
InVitro International (OTCQB: IVRO) reported FY 2025 sales of $878,937, a rise of 8.3% versus FY 2024, and net income of $121,980, up 14.3% year‑over‑year.
Management highlighted global regulatory developments saying some Regulatory Agencies have already, or will soon, cease funding animal testing and that certain agencies indicated OECD‑validated non‑animal test results could be accepted immediately. The company positions its in vitro test methods for large end markets including cosmetics, chemical companies, and adhesives manufacturers.
InVitro International (OTCQB: IVRO) reported strong financial results for Q3 FY '25, with sales reaching $234,430, marking a 39.7% increase from Q3 FY '24. Year-to-date sales hit $675,080, up 14.4% year-over-year, while net income reached $95,556 for the first three quarters, showing a 17.1% improvement.
CEO W. Richard Ulmer highlighted increasing interest from chemical companies due to cost and time advantages of in vitro testing over animal testing. The company's growth is further supported by Canada's ban on new cosmetics involving animal testing and U.S. government agencies' acceptance of validated in vitro test results.
InVitro International (OTCQB: IVRO) reported strong financial results for Q1 FY '25. The company achieved sales of $244,143, marking a 15.4% increase compared to Q1 FY '24 sales of $211,625. Net income showed significant growth, reaching $33,855, representing a 91.6% increase from the previous year's Q1 figure of $17,667.
CEO W. Richard Ulmer expressed satisfaction with the quarter's progress, highlighting the company's recently announced M&A activity in Europe. Following challenges from Covid and inflation, the company maintains a vision of continued global growth in non-animal test technologies.
InVitro International (OTCQB: IVRO) has announced signing a Memorandum of Understanding (MOU) to merge with an unnamed European-based organization specializing in non-animal testing. The target company has been operating in the European market for over 20 years. This strategic move aligns with IVRO's previously announced growth strategy focused on mergers and acquisitions.
The MOU has received unanimous approval from IVRO's Board of Directors. Financial details and timing of the merger will be disclosed upon finalization of the agreement. The company views this merger as an opportunity to expand its presence in the European market, where the non-animal testing movement originated and continues to show strong growth.
InVitro International (OTCQB: IVRO) reported its FY '24 financial results, showing mixed performance. The company achieved sales of $811,290, marking a 2.4% increase compared to FY '23, while net income significantly improved to $106,704 from $1,555 in the previous year. Fourth quarter performance showed sales growth of 19.9% reaching $221,200, although quarterly net income declined 48.8% to $25,122 compared to $49,035 in the same period last year. The company marked its 20th consecutive year of profits and expressed optimism about its M&A growth strategy and non-animal testing business prospects for FY '25.
InVitro International (OTCQB: IVRO) has announced the engagement of Askew Kabala and Company, Inc. (AKC) as a consultant to support and advance the company's corporate growth plan. AKC will provide business advising, investment banking, management, and strategy services to IVRO. The consulting firm will offer executive and organizational support, including strategy refinement, planning, and operational review.
IVRO CEO W. Richard Ulmer expressed enthusiasm about the partnership, stating that the company is adapting well to post-Covid-19 and inflationary times by adding guidance from experienced professionals. The engagement with AKC comes in the final month of IVRO's Fiscal 2024 Year, signaling a strategic move to enhance the company's growth trajectory.
InVitro International (OTCQB: IVRO) reported its Q3 FY '24 financial results, showing a 16% decrease in sales to $167,850 compared to the same quarter last year. However, the company achieved a net income of $16,236, a significant improvement from the $13,162 loss in Q3 FY'23. For the first three quarters of FY'24, sales totaled $590,090, down 3% from FY'23, but year-to-date earnings surged to $81,582, a 272% increase from the prior year's losses. CEO W. Richard Ulmer highlighted the company's focus on maintaining profitability for the 19th consecutive year and pursuing growth through M&A financing and qualifying private laboratories. Ulmer also emphasized the promising future of non-animal testing in the industry.
InVitro International reported positive second quarter FY '24 results with sales of $210,615, up 5.8% from the same period in FY '23, and net income of $47,674. First half FY '24 sales increased 3.4% to $422,240, with a net income of $65,342 compared to losses in FY '23. The company is planning an uplisting to OTCQB to enhance visibility and credibility with potential M&A targets.
Summary not available.
Summary not available.
FAQ
What is the current stock price of Invitro Internat (IVRO)?
What is the market cap of Invitro Internat (IVRO)?
